Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development

Oncologist - United States
doi 10.1634/theoncologist.12-7-840
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Alphamed Press

Related search

Atezolizumab for the First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC): Current Status and Future Prospects

Frontiers in Oncology
Cancer ResearchOncology
2018English

Adjuvant Therapy in Non-Small Cell Lung Cancer: Current and Future Directions

Oncologist
Cancer ResearchMedicineOncology
2010English

ILD During Erlotinib and Gefitinib Treatment in Japanese Patients With Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2010English

Small Cell Lung Cancer: Current and Future Strategies

Oncomedicine
2016English

Erlotinib Treatment in Pretreated Patients With Non-Small Cell Lung Cancer: A Phase II Study

Oncology Letters
Cancer ResearchOncology
2010English

Individualized Therapy in Non-Small-Cell Lung Cancer: Future Versus Current Clinical Practice

Oncogene
Cancer ResearchGeneticsMolecular Biology
2009English

Successful Treatment of Non-Small Cell Lung Cancer With Gefitinib After Severe Erlotinib-Related Hepatotoxicity

Internal Medicine
Internal MedicineMedicine
2012English

Maintenance Therapy for Advanced Non-Small Cell Lung Cancer: Current Status, Controversies, and Emerging Consensus

Clinical Cancer Research
Cancer ResearchOncology
2010English

Inequalities in Non-Small Cell Lung Cancer Treatment and Mortality

Journal of Epidemiology and Community Health
EpidemiologyPublic HealthOccupational HealthEnvironmental
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy